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Résumé: Aim of the Study
Critically ill populations often have shown subtherapeutic aminoglycosides'
concentrations mostly because of unavoidable changes in drug volume distribution and
clearance. We present a real life prospective study evaluating  plasma concentrations
for once-daily dosing foramikacin and gentamycin among a population of severe burn
adults.
Methods
We conducted a real life prospective study on the plasma concentrations of amikacin
and gentamycin among severe burn patients, using aminoglycoside as combination
therapy. Antibiotics were prescribed at the standard doses of 15-20 mg/kg/day for
amikacin and 3-5mg/kg/day for gentamycin
Results
Eight patients (4 in amikacin and 4 in gentamycin groups, respectively) were enrolled
in the study. All subjects were admitted for severe burns. The most common site of
infection was bloodstream (5; 62.5%) and pneumonia (4; 50%).  Pseudomonas
aeruginosa  , followed by  Klebsiella pneumoniae  and multi-drug resistant
Acinetobacter baumannii  were the most prevalent agents isolated. Amikacin and
gentamycin never achieved the target peak concentration of 60mg/L and 30mg/L: in
our study C  max  , for amikacin, was 33.1 ±15.6mg/L (SD), while for gentamycin was
14.3 mg/L ±9. C  max    and total body surface area have shown a strong negative
correlation with borderline statistical significance (amikacin: ρ= 0.922, p=0.078;
gentamycin: ρ=0.937, p=0.063). At the standard dosage, the
pharmacokinetic/pharmacodynamic (PK/PD) target of Cmax > 8 x highest MIC was
reached for 8 (53.3%) out of 15 isolated pathogens.
Conclusions
The present study found that, in a population of septic burn patients, standard doses of
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gentamycin and amikacin most often lead to plasma concentrations under the PK/PD
target
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Turin, September 19th 2020 
 
Dear Editor, 
Thanks for the opportunity to revise our manuscript. Please find the response to reviewers’ 
comments on our manuscript entitled “Observed concentrations of Amikacin and Gentamycin in 
the Setting of Burn Patients with Gram-Negative Bacterial infections: preliminary data from 




Thanks you for your revision which improve the manuscript. Few issues are still remaining. 
 
1) Discussion section: Please modify the following sentence in order to improve understanding 
: "Thirdly, we use exact MIC value and clinical breakpoints in the pharmacological analysis, 
despite that using ECOFF as MIC value is more appropriate in ICU than the use of clinical 
breakpoints for defining PK-PD targets of an antibiotic treatment" to "Thirdly, in the PK-PD 
analysis we use clinical breakpoints when exact MIC value were not available, despite that 
using ECOFF as MIC value is more appropriate in ICU population (Guilhaumou et al., 
Critical Care, 2019)." 
 
Thank you for these corrections. The sentence was modified in the text. 
 
2) Conclusion:  Line 20-21 page 5 : Please correct « concetrations ». 
 
Thank you for these correction. The word was corrected in the text. 
 
3) Ethics approval: Please correct the discrepancy between "Ethics approval and consent to 
participate section" ("Informed consent was waived due to the retrospective nature of the 
study. The study was performed by ICH-GCP guidelines and the declaration of Helsinki") 
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and "Methods" section ("The study was approved by the local ethical committee (PROT. 
N.0063741) and written informed consent was obtained from all patients before the 
sampling"). 
 
Thank you for this suggestion that improve the manuscript. Right formi s the second one, presented 
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Aim of the study.- Critically ill populations often have shown subtherapeutic aminoglycosides' 
concentrations mostly because of unavoidable changes in drug volume distribution and clearance. 
We present a real life prospective study evaluating plasma concentrations for once-daily dosing for 
amikacin and gentamycin among a population of severe burn adults. Methods.- We conducted a real 
life prospective study on the plasma observed concentrations of amikacin and gentamycin among 
severe burn patients, using aminoglycoside as combination therapy. Antibiotics were prescribed at 
the standard doses of 15-20 mg/kg/day for amikacin and 3-5mg/kg/day for gentamycin. Results.- 
Eight patients (4 in amikacin and 4 in gentamycin groups, respectively) were enrolled in the study. 
All subjects were admitted for severe burns. The most common site of infection was bloodstream 
(5; 62.5%) and pneumonia (4; 50%). Pseudomonas aeruginosa, followed by Klebsiella pneumoniae 
and multi-drug resistant Acinetobacter baumannii were the most prevalent agents isolated. 
Amikacin and gentamycin never achieved the target peak concentration of 60mg/L and 30mg/L: in 
our study Cmax, for amikacin, was 33.1 ±15.6mg/L (SD), while for gentamycin was 14.3 mg/L ±9. 
Cmax  and total body surface area have shown a strong negative correlation with borderline 
statistical significance (amikacin: ρ= 0.922, p=0.078; gentamycin: ρ=0.937, p=0.063). At the 
standard dosage, the pharmacokinetic/pharmacodynamic (PK/PD) target of Cmax > 8 x highest MIC 
was reached for 8 (53.3%) out of 15 isolated pathogens. Conclusions.- The present study found that, 
in a population of septic burn patients, standard doses of gentamycin and amikacin most often lead 
to plasma concentrations under the PK/PD target 
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Cmax: peak drug concentration 







































































MIC: minimum inhibitory concentration 
PD: pharmacodynamic 
PK: pharmacokinetic 
TBSA: total body surface area 
TDM: therapeutic drug monitoring 




Aminoglycosides (AGs) have been commonly used as a part of the combination regimen for 
managing bacterial infections in severe burn patients, increasing the chance of initial effective therapy 
[1]. Infection is the most frequent complication encountered by burn patients, with a high risk of 
gram-positive isolates immediately after hospital admission and a risk of gram-negative bacteria that 
increases with the length of hospital stay [2-3]. AGs display a concentration-dependent killing 
activity; thus, the rate and extent of bacterial killing are driven by peak drug concentrations (i.e., Cmax) 
[4]. Pharmacodynamic, bacteriological and toxicological expertise have allowed for increasingly 
higher usage of aminoglycosides in once-daily dosing regimens, due to its ability to achieve desirable 
antibiotic blood concentration and potentially reduce the risk of nephrotoxicity [5]. Severe burn 
patients often show subtherapeutic AG concentrations, mostly due to changes in volume distribution 
(Vd) and clearance [6]. Hence, the pharmacodynamic (PD) target – the ratio of Cmax to the minimum 
inhibitory concentration (MIC) ≥8 (notably by eight-fold to twelve-fold) after the first dose – is often 
difficult to achieve [6]. A weight-based dose adjustment scheme, commonly known as the Hartford 
nomogram, has been recommended for the treatment of gram-negative infections; dosing correction 
was based on pharmacokinetic (PK) data derived from the general patient population [7]. However, 
the recommended AG dose is likely to be insufficient to achieve target peak drug concentrations in 
critically ill patients due to differences in PK compared with the general patient population. PK 
parameters AG are much more variable in critically ill patients, and in the severe burn patients 




































































frequent dose changes and therapeutic drug monitoring (TDM) practice to achieve therapeutic 
antibiotic concentrations and maximise effectiveness and safety [8-11].  
We aimed to describe observed concentrations of amikacin (AMK) and gentamycin (GEM) 





We conducted a real life prospective study on the plasma concentrations of AMK and GEM among 
severe burn patients. Antibiotics were prescribed at the standard, in label, doses of 15-20 mg/kg/day 
for AMK and 3-5 mg/kg/day for GEM. The target peak concentrations (Cmax) for AMK and GEM 
were, respectively, 60 mg/L and 30 mg/L, according to the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) definitions, and the target pharmacokinetic/pharmacodynamic 
(PK/PD) ratio was defined as a Cmax >8 x highest MIC [12]. Both drugs were given intravenously 
(IV) over 30 minutes, either as empirical or targeted therapy. The study was approved by the local 
ethical committee (PROT. N.0063741) and written informed consent was obtained from all patients 
before the sampling. All subjects admitted to the Burn Center of Turin, Italy from January 2016 to 
April 2018 and treated with AMK or GEM, either empirically or as target therapy, were enrolled in 
the study. Complete demographic characteristics, medical histories and clinical parameters were 
collected from each subject, including days of hospitalisation, blood chemistries, renal function and 
specific burn indices. Sepsis and septic shock were classified according to the Third International 
Consensus Definition (Sepsis-3) [13]. Microbiological data, where available, were also collected. 
Plasma aminoglycosides concentrations were determined at steady-state ≥48 h after the 
beginning of therapy. The first blood sampling was performed immediately before the antibiotic 
administration (T0) and, another sample was obtained at the end of the infusion (T1). The Cmax is 
defined as the concentration at the end of the infusion. Blood samples were collected in lithium 
heparin tubes (7 mL) and plasma was obtained by centrifugation at 1400 X g for 10 min at 4 °C (ALC 
PK 130R refrigerated centrifuge; DJB Labcare Ltd., Newport Pagnell, UK). Each sample was stored 
at - 20 °C until analysis (<3 weeks). Stability tests performed during method validation reported drug 




































































determined in the setting of routine clinical care via the HPLC-photodiode method (HPLC-
photodiode array). 






Eight patients were enrolled in the study – four in the AMK treatment group and four in the GEM 
treatment group. Patients’ characteristics are shown in Table 1. All subjects were admitted for severe 
burns, involving 10–55% of their total body surface area (TBSA), with a mean Revised Baux Score 
of 104.5 ± 50.4. Six patients (75%) required mechanical ventilation and two had septic shock [13]. 
The most common sites of infection were the bloodstream (5; 62.5%) and pneumonia (4; 50%). In 
three cases (37.5%), infection involved more than one site. The most frequently isolated bacteria were 
Pseudomonas aeruginosa, followed by Klebsiella pneumoniae and multidrug-resistant Acinetobacter 
baumannii (Table 2). The administration of 15–20 mg/kg of AMK and 3–5 mg/kg of GEM never 
achieved the respective target peak concentrations of 60 mg/L and 30 mg/L (Table 2). The mean Cmax 
was 33.1 ± 15.6 mg/L (SD) for AMK and 14.3 mg/L ±9 (SD) for GEM. Cmax values for both AMK 
and GEM were negatively correlated with burn surface area (e.g., TBSA), with borderline statistical 
significance (AMK: ρ = 0.922, p = 0.078; GEM: ρ = 0.937, p = 0.063). At the standard dosage, the 
PK/PD target of Cmax >8 x highest MIC was reached for 8 (53.3%) out of 15 isolated pathogens. No 





Complex haemodynamic changes occurring in critically ill burn patients may be different depending 
on the phase after the burn injury [8]. In the early phase, there is a greater volume of distribution (Vd) 
that may be due to weight gain secondary to aggressive IV fluid resuscitation (i.e., Parkland formula), 




































































predictive markers for AG clearance, along with Vd, and it is linked to the presence of renal 
dysfunction: decreased urine output may denote low renal blood flow and AG clearance, on the other 
hand in the absence of organ dysfunction, AG output could result consistently increased [6-7]. Altered 
pharmacokinetics in burn patients may affect antibiotic plasma concentrations and, in most studies, 
the Cmax for aminoglycosides was always below therapeutic plasma level, with high interindividual 
variability [10]. However, these changes are generally not considered when deciding upon antibiotic 
doses for these patients, despite Beaucaire et al. showing a worse outcome in critically ill patients 
when the Cmax remained at < 40 g/mL [13]. We reported the PK /PD characteristics of a single daily 
dose of AMK and GEM, at the standard doses of 15-20 mg/kg and 3-5 mg/kg, respectively, in a small 
population of burn patients with severe infections caused by gram-negative bacteria. We observed 
that the standard doses of AMK and GEM never achieved the respective target peak concentrations 
of 60 mg/L and 30 mg/L, with low mean Cmax values (33.1 mg/L and 14.3 mg/L, respectively). Conil 
and colleagues [14] showed that administration of higher doses, particularly of AMK, (e.g., 20 mg/kg) 
was insufficient to ensure the goal of Cmax/MIC ratio up to six-fold, achieved in only 47% (18/28) of 
cases. Several studies used TDM with dose modification to achieve concentrations within a 
predefined range in the general population: AMK at a standard dosage of 14–15 mg/kg has reached 
target concentration range in 91–100% [15], while GEM at a dosage of 5–7 mg/kg has reached target 
concentration range in 96–98% [16]. In Jenkins et al. [15] and Plajer et al. [16] studies target 
concentrations were achieved with satisfactory percentages through higher dosages of 
aminoglycosides compared to this cohort and with the use of TDM. Our population statistical analysis 
demonstrated a negative relationship between Cmax and the area of the burn for AMK and GEM, as 
previously reported by Conil et al. [14], with a strong correlation but with borderline statistical 
significance, likely due to the low number of patients. Moreover, in this small sample, PK/PD target 
for efficacy (Cmax/MIC ≥8) was reached in 53.3%. of subjects No theoretical drug or drug interactions 
have been observed with concomitant therapies. Higher doses of AG were investigated in a 
subsequent study by Roger et al. in a non-burnt critically ill population: only 59% of patients led to 
target peak serum concentrations after the administration of 30 mg/kg and 8 mg/kg of AMK and 
GEM, respectively [10]. Low peak AG concentrations were also confirmed in other studies that 
proposed higher dosages or intensive TDM [5-7]. This study had several limitations. First, the number 
of patients receiving AMK or GEM was too small for the assessment of the impact of confounding 
factors, such as co-morbidities or synergism or drug interactions with chronic or concomitant 
therapies, that might have led to further reductions or modifications in peak concentrations. Secondly, 




































































in the PK-PD analysis we use clinical breakpoints when exact MIC value were not available, despite 





We reported preliminary data from a small, single-centre, real life prospective study on PK/PD of 
aminoglycosides in burn patients. In literature, most of data on PK/PD and observed concentrations 
of aminoglycosides are retrospective analysis and no prospective trial. In our prospective study we 
found that in a population of septic burn patients, standard doses of GEM and AMK most often lead 
to plasma concentrations under the PK/PD target and peak concentrations might be significantly 
lower in burn patients compared to those described in critically ill patients [5, 14]; therefore, it may 
be helpful using higher doses of AMK and GEM, using TDM in clinical practice  to avoid sub-optimal 
therapies and to avoid overexposure and toxicity.  
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Table 1. Patient characteristics and plasma concentrations 






















































































Legend (Table 2): GEM: gentamicin; AMK; amikacin; MIC (exact): minimum inhibitory concentration; C: 
concentration; MSSA: Methicillin-susceptible S.aureus; S: sensible; R: resistant; AG: aminoglycosides 
Table 2: Microbiological Features and Observed Concentrations 
Legend (Table 1): S.D. : standard deviation; GEM: gentamicin; AMK; amikacin; BMI: body mass index; M: male; 
F: female; TBSA: total burn surface area; RBS: revised BAUX score; CVVH: continuous veno-venous 
hemofiltration; MIC: minimum inhibitory concentration; C: concentration 
Table 1: Patient Characteristics and Plasma Concentrations 
Tables
